GSDME and colorectal carcinoma: The chemotherapeutic agent, lobaliplatin, acts by inducing GSDME-mediated pyroptosis in CRC cells (Yu et al., 2019), while decitabine, a DNA methylase inhibitor, increases GSDME, thereby boosting cell sensitivity to certain anticancer drugs (Wang et al., 2017).